CDSCO bars injectable cosmetics, jolts India's $1.6B medical aesthetics market
India's drug regulator issued a public notice prohibiting injectable cosmetic products and misleading claims, putting aesthetic clinics, beauty marketers and manufacturers on notice. The crackdown covers dermal fillers, botulinum toxin and skin-brightening injectables — a category the industry pegs at $1.6 billion in 2024 and growing toward ₹13,000 crore.
What happened
CDSCO issued a public notice barring injectable cosmetic products and misleading claims, warning aesthetic clinics, beauty marketers and manufacturers. Move
Key facts
- $1.6 billion 2024 market
- ₹13,000 crores
Why this matters
Distressed assets and licensing gaps will emerge across injectable brands and clinic networks—line up diligence on compliant pharma-grade players who can acquire share as non-compliant competitors retreat.